Clinical Trials /

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

NCT02809053

Description:

This is a Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the statistical equivalence of efficacy, safety and immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in asymptomatic patients with Low Tumor Burden Follicular Lymphoma.

Related Conditions:
  • Follicular Lymphoma
Recruiting Status:

Active, not recruiting

Phase:

Phase 3

Trial Eligibility

Document

Title

  • Brief Title: A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
  • Official Title: A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Clinical Trial IDs

  • ORG STUDY ID: AGB002
  • NCT ID: NCT02809053

Conditions

  • Lymphoma, Follicular

Interventions

DrugSynonymsArms
SAIT101SAIT101
MabThera®RituximabMabThera®

Purpose

This is a Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the statistical equivalence of efficacy, safety and immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in asymptomatic patients with Low Tumor Burden Follicular Lymphoma.

Detailed Description

      This is a Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the
      statistical equivalence of efficacy, safety and immunogenicity of SAIT101 Versus Rituximab as
      a First-line Immunotherapy Treatment in asymptomatic patients with Low Tumor Burden
      Follicular Lymphoma. Patients will be randomized in a 1:1 ratio to receive study drug once a
      week for 4 weeks, and will then be followed up for up to 52 weeks after the first dose.
      Randomization will be stratified by inclusion in the PK/PD sub-population and Follicular
      lymphoma international prognostic index 2 (FLIPI-2) score.

      Visits are scheduled at Weeks 1, 2, 3, and 4 (study drug infusion visits), and then at Weeks
      5, 12, 20, 28, 36, and 52 (i.e., End of Study [EOS]). Efficacy response assessments will be
      performed at Weeks 12 and 28, while safety assessments will continue until EOS.

      The primary objectives is To compare the efficacy of SAIT101 with rituximab licensed in the
      European Union (hereafter designated MabThera®, brand name in EU) when administered as a
      first-line immunotherapy in patients with low tumor burden follicular lymphoma (LTBFL) and
      the secondary objectives isTo evaluate SAIT101 versus MabThera® with respect to safety and
      tolerability, immunogenicity and Pharmacokinetics (PK)/Pharmacodynamics (PD) in a
      sub-population of patients.
    

Trial Arms

NameTypeDescriptionInterventions
SAIT101Experimental
    MabThera®Active Comparator

      Eligibility Criteria

              Inclusion Criteria:
      
                1. Patients with histologically-confirmed Low Tumor Burden Follicular Lymphoma, without B
                   symptoms, Ann Arbor stage II to IVA NHL (CD20+ FL of Grades 1, 2, or 3a)
      
                2. Low tumor burden according to GELF criteria defined as:
      
                     -  Normal serum lactate dehydrogenase (LDH)
      
                     -  No mass ≥7 cm.
      
                     -  Less than 3 nodal sites, each with diameter >3 cm
      
                     -  No systemic or B symptoms (fever >38°C for 3 consecutive days; recurrent,
                        drenching night sweats; unintentional weight loss exceeding 10% body weight in
                        the last 6 months.
      
                     -  No splenomegaly ≥16 cm by CT scan.
      
                     -  No risk of vital organ compression.
      
                     -  No pleural or peritoneal serous effusion.
      
                     -  No leukemic phase >5,000/µL circulating tumor cells.
      
                     -  No cytopenias (defined as platelets <100,000/mm3, hemoglobin <10 g/dL, or
                        absolute neutrophil count <1,500/mm3).
      
                3. Patients not previously treated for their FL, including any previous treatment for FL
                   under clinical trials except localized radiation therapy for previous limited stage
                   disease.
      
              Exclusion Criteria:
      
                1. Previous treatment with any chemotherapy and/or rituximab or other monoclonal
                   antibody.
      
                2. Prior radiotherapy completed <28 days before study enrollment.
      
                3. Anticipated need for concomitant administration of any other experimental drug, or a
                   concomitant chemotherapy, anticancer hormonal therapy, radiotherapy, or immunotherapy
                   during study participation.
      
                4. Concomitant disease which requires continuous therapy with corticosteroids at doses
                   equivalent to prednisolone >20 mg/day.
      
                5. Transformation to high-grade lymphoma secondary to previously untreated low-grade
                   lymphoma.
      
                6. Prior or concomitant malignancies within 5 years prior to screening, with the
                   exceptions of non-melanoma skin cancer, adequately treated carcinoma in situ of the
                   cervix, adequately treated breast cancer in situ, and localized prostate cancer stage
                   T1c, provided that the patient underwent curative treatment and remains relapse free.
      
                7. Patients with a body surface area >3.0 m2.
      
                8. Major surgery (excluding lymph node biopsy) within 28 days prior to randomization.
      
                9. Primary or secondary immunodeficiency (history of, or currently active), including
                   known history of human immunodeficiency virus (HIV) infection or positive test at
                   screening.
      
               10. Acute, severe infection (e.g., sepsis and opportunistic infections), or active,
                   chronic or persistent infection that might worsen with immunosuppressive treatment
                   (e.g., herpes zoster).
      
               11. Positive serological test for hepatitis B surface antigen (HBsAg), hepatitis B core
                   antibody (HBcAb) or hepatitis C serology.
      
               12. Confirmed current active tuberculosis (TB)
      
               13. Central nervous system (CNS) or meningeal involvement, or cord compression by the
                   lymphoma; history of CNS lymphoma
      
               14. History of a severe allergic reaction or anaphylactic reaction to a biological agent
                   or history of hypersensitivity to any component of the trial drug (e.g.,
                   hypersensitivity or allergy to murine products).
      
               15. Patients who have significant cardiac disease, including but not limited to history of
                   congestive heart failure (New York Heart Association Class III/IV; see Appendix 7),
                   unstable angina, or uncontrolled cardiac arrhythmia.
      
               16. Uncontrolled or severe hypertension, or cerebrovascular disease.
      
               17. Serious underlying medical conditions that, per the Investigator's discretion, could
                   impair the ability of the patient to participate in the trial
      
               18. Any other co-existing medical or psychological condition(s) that will preclude
                   participation in the study or compromise ability to give informed consent and/or
                   comply with study procedures.
      
               19. Treatment with any investigational medicinal product (IMP) within 4 weeks prior to
                   initiation of 1st infusion of study drug, or treatment with a drug that has not
                   received regulatory approval for any indication within 4 weeks or a minimum of 5
                   half-lives, whichever is longer, of the 1st infusion of study drug.
      
               20. Receipt of a live/attenuated vaccine within 6 weeks prior to the screening visit.
      
               21. Females who are pregnant, breastfeeding, or planning a pregnancy during the treatment
                   period or within 12 months after the last infusion of study drug.
      
               22. Patients who are investigational site staff members directly involved in the conduct
                   of the trial, and their family members, site staff members otherwise supervised by the
                   investigator, or patients who are Archigen employees directly involved in the conduct
                   of the trial.
            
      Maximum Eligible Age:N/A
      Minimum Eligible Age:18 Years
      Eligible Gender:All
      Healthy Volunteers:No

      Primary Outcome Measures

      Measure:Overall Response Rate (ORR)
      Time Frame:Week 28
      Safety Issue:
      Description:Overall Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) at Week 28, as defined by International Working Group (IWG) criteria 2007

      Secondary Outcome Measures

      Measure:Tumor response evaluations
      Time Frame:Weeks 12 and 28
      Safety Issue:
      Description:Tumor response evaluations as defined by the revised IWG Criteria 2007, for malignant lymphoma

      Details

      Phase:Phase 3
      Primary Purpose:Interventional
      Overall Status:Recruiting
      Lead Sponsor:Archigen Biotech Limited

      Trial Keywords

      • low tumor burden follicular lymphoma (LTBFL)

      Last Updated

      August 9, 2017